Invest in intelligence that delivers

Spherix Market Expertise

Our team of experts and curated communities of prescribers, patients and payers give you a competitive edge.

See the market from the decision maker’s point of view.

Our physician, payer, and patient communities represent curated networks of your targeted prescribers, KOLs influencing your products, commercial and government payers making crucial access decisions, executives from integrated health networks, and the patients who rely on your innovations. These relationships keep us closely connected with the specific challenges and opportunities within specialty markets.

Vetted
Practicing Physicians

Key Opinion
Leaders

Professional Organizations

Market Access Stakeholders ​

Patients

Our experts are always just a click or call away...

  • Plugged into the ever-evolving landscape
  • Ready to provide an unbiased view of the landscape
  • Insightfully answer real-time questions
  • Highlight opportunities 
  • Identify disruptors

Market Access

Expertise

11

dedicated team members

75+

years of
market research experience

20

studies published annually

Areas of Focus

  • Commercial Benefits
  • Government Benefits
  • Employer Access Influence

Team Lead

Sybil Mead
Vice President of Market Access

Sybil Mead is a seasoned healthcare access and reimbursement expert. With more than 20 years of experience in market access, government programs, strategic consulting, and market research, Sybil has expertise in Medicare policy, managed care, and access. She previously directed Medicare, Medicaid, and commercial payer research services, contributing to influential reports on Medicare Part D, Part B reimbursement changes, and broader policy impacts on biopharma access. Sybil holds a Master of Public Policy from the University of Chicago and a Bachelor of Arts from Cornell University.

CNS

Expertise

7

dedicated team members

11

years of
continuous tracking

22

studies published annually

Indications

  • Alzheimer’s Disease (AD)
  • Alzheimer’s Disease Psychosis
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Depressive Mood Disorders
  • Epilepsy
  • Generalized Myasthenia Gravis (gMG)
  • Migraine
  • Multiple Sclerosis (MS)
  • Schizophrenia

Team Lead

Sarah Soucy

Franchise Head, CNS

Sarah is a healthcare market research professional with over 10 years of experience in pharmaceutical insights and analytics. Over the course of her career, she has held leadership roles at RxY, REACH Market Research, and Decision Resources Group (Clarivate).

Dermatology

Expertise

7

dedicated team members

11

years of
continuous tracking

25

studies published annually

Indications

  • Alopecia Areata (AA)
  • Asthma
  • Atopic Dermatitis (AD)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Chronic Spontaneous Urticaria (CSU)
  • Hidradenitis Suppurativa (HS)
  • Plaque Psoriasis (PsO)
  • Prurigo Nodularis (PN)
  • Vitiligo

Team Lead

Andy Stankus
Franchise Head, Dermatology

Andy, with a pharmaceutical marketing MBA, has 27+ years of experience in life sciences and healthcare consultancy creating commercial strategy, differentiation and real-world value.  Prior to Spherix, Andy led global product launches at Johnson & Johnson, data and research consulting teams at Kantar Health / Oracle Life Sciences, and enjoys publishing and speaking across multiple therapeutic areas at international conferences.  In addition to this broad therapeutic expertise, given a specific passion in dermatology, Andy and teams he has led have been lead authors on more than 145 dermatology publications across 20+ life sciences organizations.

Gastroenterology

Expertise

7

dedicated team members

11

years of
continuous tracking

25

studies published annually

Indications

  • Celiac Disease
  • Cholestatic Pruritus (CP)
  • Crohn’s Disease (CD)
  • Eosinophilic Esophagitis (EoE)
  • Irritable Bowel Syndrome (IBS)
  • Metabolic Dysfunction-Associated Steatohepatitis (MASH)
  • Obesity
  • Primary Biliary Cholangitis (PBC)
  • Primary Sclerosing Cholangitis (PSC)
  • Ulcerative Colitis (UC)

Team Lead

Jim Hickey
Franchise Head, Gastroenterology

Jim has 20+ years’ experience building and leading research teams, pioneering innovative research techniques, and providing insight solutions to pharmaceutical brands. Prior to Spherix, he led the research team at Verilogue from early startup through its acquisition by Publicis Health. Jim has extensive experience across a wide range of therapeutic categories and a particular interest in gastroenterology and inflammatory disease.

Rheumatology

Expertise

7

dedicated team members

11

years of
continuous tracking

24

studies published annually

Indications

  • Ankylosing Spondylitis and nr-AxSpA
  • Cutaneous Lupus (CLE)
  • Giant Cell Arteritis (GCA)
  • Idiopathic Inflammatory Myopathies (IIM)
  • Interstitial Lung Disease (ILD)
  • Lupus Nephritis (LN)
  • Psoriatic Arthritis (PsA)
  • Rheumatoid Arthritis (RA)
  • Sjögren’s Disease (SjD)
  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis (SSc)

Team Lead

Lynn Price
Franchise Head, Rheumatology

Lynn has over eight years at Spherix, leading
strategic initiatives and insights development.
She previously, directed research analytics at
Decision Resources Group and managed
immunology research at BioTrends, with
extensive experience in data analysis and
client relations in the biopharmaceutical
sector.

Nephrology

Expertise

8

dedicated team members

11

years of
continuous tracking

25

studies published annually

Indications

  • Chronic Kidney Disease, Non-Dialysis (CKD-ND)
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Hyperkalemia
  • Hyperphosphatemia (HPhos)
  • IgA Nephropathy (IgAN)
  • Membranous Nephropathy (MN)
  • Renal Anemia
  • Transplant / Antibody-Mediated Rejection (AMR)

Team Lead

Kari McCarthy
Franchise Head, Nephrology

Kari has more than 20 years of experience in healthcare, strategy and insights, with a strong track record in brand development, market research, and strategic narrative building. Most recently, Kari was the VP of Strategy at DDB Health, where she led brand strategy for nephrology and oncology brands. 

Ophthalmology

Expertise

7

dedicated team members

4

years of
continuous tracking

11

studies published annually

Indications

  • Age-Related Macular Degeneration, (AMD)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)
  • Geographic Atrophy (GA)
  • Thyroid Eye Disease (TED)

Team Lead

Sarah Soucy

Franchise Head, Ophthalmology

Sarah is a healthcare market research professional with over 10 years of experience in pharmaceutical insights and analytics. Over the course of her career, she has held leadership roles at RxY, REACH Market Research, and Decision Resources Group (Clarivate).

Hematology

6

dedicated team members

3

years of
continuous tracking

10

studies published annually

Indications

  • Bleeding Disorders
  • Hemophilia A & B
  • Immune Thrombocytopenic Purpura (ITP)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Sickle Cell Disease (SCD)
  • Thalassemia
  • Von Willebrand Disease (VWD)
  • Warm Autoimmune Hemolytic Anemia (wAIHA)
  • Women, Girls, and People Who Menstruate (WGPPM)

Team Lead

Sarah Hendry

Franchise Head, Hematology

Sarah has over a decade of experience managing custom and syndicated projects, specializing in hematology/oncology.  She brings deep expertise in brand strategy and patient-centered communications within healthcare and pharma. Most recently, Sarah led brand strategy execution for CAR-T therapies at DDB Health, working closely with pharmaceutical partners to enhance engagement and brand growth. In her previous research roles at Verilogue and Maslansky + Partners, she worked extensively in hematology, including co-authoring an article in the Orphanet Journal of Rare Diseases on the lexicon for gene therapy in hemophilia B, communicating the complement cascade in PNH, and analyzing market dynamics in myeloma and B-cell malignancies.

Oncology

NEW
2025!

6

dedicated team members

10

studies published annually

Indications

  • Acute Myeloid Leukemia (AML)
  • B-Cell Malignancies
  • Chronic Lymphocytic Leukemia (CLL)
  • Large B-Cell Lymphoma (LBCL)
  • Multiple Myeloma (MM)
  • Myeloproliferative Neoplasms (MPN)
  • Non-Small Cell Lung Cancer (NSCLC)
  • Smoldering Myeloma (SMM)
  • Solid Tumors

Team Lead

Sarah Hendry

Franchise Head, Oncology

Sarah has over a decade of experience managing custom and syndicated projects, specializing in hematology/oncology.  She brings deep expertise in brand strategy and patient-centered communications within healthcare and pharma. Most recently, Sarah led brand strategy execution for CAR-T therapies at DDB Health, working closely with pharmaceutical partners to enhance engagement and brand growth. In her previous research roles at Verilogue and Maslansky + Partners, she worked extensively in hematology, including co-authoring an article in the Orphanet Journal of Rare Diseases on the lexicon for gene therapy in hemophilia B, communicating the complement cascade in PNH, and analyzing market dynamics in myeloma and B-cell malignancies.

Sign up for alerts, market insights and exclusive content in your inbox.